COMMUNIQUÉS West-GlobeNewswire

ProQR Announces Extraordinary General Meeting of Shareholders

27/12/2017 - 13:00

LEIDEN, the Netherlands, Dec. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq: PRQR ), today announced that an Extraordinary General Meeting of Shareholders will be held on Monday, February 19, 2018, at 16: [...]

Blood donors step up, but more still needed

27/12/2017 - 13:00

OTTAWA, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Canadian Blood Services has seen a notable increase in donations since Dec. 18 when it issued an urgent call for eligible donors to fill 35,000 open appointments by Jan. 6. [...]

VBL Therapeutics Announces First Patient in Pivotal Phase 3 Study of VB-111 in Platinum Resistant Ovarian Cancer in Collaboration with the GOG Foundation, Inc.

27/12/2017 - 13:00

TEL AVIV, Israel, Dec. 27, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) today announced the study initiation and first patient in its Phase 3 pivotal registration trial, OVAL, studying its lead candidate VB [...]

Medigus Announces First MUSE(TM) Procedure for the Treatment of GERD Performed in Israel at Shaare-Zedek Medical Center

27/12/2017 - 13:00

OMER, Israel, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and an innovator in direct visualization technology, [...]

Novo Nordisk A/S: Share repurchase programme

27/12/2017 - 11:43

Bagsværd, Denmark, 27 December 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]

Orion Corporation: Managers' transactions - Westerlund Riikka

27/12/2017 - 08:46

ORION CORPORATION MANAGERS' TRANSACTIONS 27 DECEMBER 2017 at 9.45 EET Orion Corporation: Managers' transactions - Westerlund Riikka Orion Corporation has received the following disclosure under Market Abuse Regulation ( [...]

Herantis Pharma expands on timeline for Lymfactin studies

27/12/2017 - 08:01

Herantis Pharma expands on timeline for Lymfactin® studies Herantis Pharma Plc Company release 27 December 2017 at 9:00 am Herantis Pharma Plc's ("Herantis") announces a slight delay in completing patient recruitment in [...]

NOTICE IN RELATION TO WAIVER OF LOCK-UP RESTRICTION

27/12/2017 - 07:01

REGULATED INFORMATION GHENT, Belgium, 27 December 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities LLC and Jefferies [...]

NANOBIOTIX : FDA approves Nanobiotix's first Immuno-Oncology trial

26/12/2017 - 23:30

FDA APPROVES NANOBIOTIX'S FIRST IMMUNO-ONCOLOGY TRIAL: A PHASE I/II STUDY OF NBTXR3 ACTIVATED BY RADIATION THERAPY (SABR) FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER OR HEAD AND NECK SQUAMOUS CELL CARCINOMA CANCER [...]

NANOBIOTIX : La FDA donne son accord pour le lancement du premier essai d'Immuno Oncologie de Nanobiotix

26/12/2017 - 23:30

LA FDA DONNE SON ACCORD POUR LE LANCEMENT DU PREMIER ESSAI D'IMMUNO ONCOLOGIE DE NANOBIOTIX : UNE PHASE I/II AVEC NBTXR3 ACTIVE PAR RADIOTHERAPIE (SABR), CHEZ DES PATIENTS ATTEINTS DE CANCER DU POUMON NON A PETITES [...]

NANOBIOTIX : 2017 review and 2018 expected milestones

26/12/2017 - 23:27

Nanobiotix: 2017 review and 2018 expected milestones Paris, France and Cambridge, Massachusetts, USA, December 26, 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company [...]

NANOBIOTIX : revue de l'année 2017 et perspectives 2018

26/12/2017 - 23:27

Nanobiotix : revue de l'année 2017 et perspectives 2018 Paris, France et Cambridge, Massachusetts, USA, 26 décembre 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), société française pionnière en nanomédecine [...]

HTG Molecular Diagnostics Expands its Collaboration with Merck KGaA, Darmstadt, Germany

26/12/2017 - 22:01

Signs Master Collaboration Agreement for Assay Development and Manufacturing of Kits Supporting Biomarker Research Programs TUCSON, Ariz. and DARMSTADT, Germany, Dec. 26, 2017 (GLOBE NEWSWIRE) -- HTG Molecular [...]

UPDATE - Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC

26/12/2017 - 17:41

LOUISVILLE, Colo., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Rezolute , Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies [...]

FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as Investigational Treatment for Prader-Willi Syndrome

26/12/2017 - 14:30

PHOENIX, Dec. 26, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY ), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD [...]

Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D., as President and Chief Executive Officer

26/12/2017 - 14:05

TUSTIN, Calif., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM ) (NASDAQ: PPHMP ), a company committed to improving patient lives by manufacturing and delivering high quality biologics, [...]

Organovo Receives Orphan Designation From U.S. FDA for 3D Bioprinted Therapeutic Liver Tissue Treatment of Alpha-1 Antitrypsin Deficiency

26/12/2017 - 14:05

SAN DIEGO, Dec. 26, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO ) (“Organovo”) today announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation for the Company’s [...]

India Globalization Capital to use Blockchain to Address Issues Specific to the Medical Cannabis Industry

26/12/2017 - 14:00

BETHESDA, Md., Dec. 26, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC), today announces that it will leverage its existing team of technology and healthcare experts to develop methods [...]

Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC

26/12/2017 - 14:00

LOUISVILLE, Colo., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Rezolute , Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies [...]